现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • ML 218 hydrochloride
ML 218 hydrochloride的可视化放大

ML 218 hydrochloride

ML 218 hydrochloride 是一种有效的、选择性的和具有口服活性的 T 型 Ca2+ 通道 (Cav3.1, Cav3.2, Cav3.3) 抑制剂,对 Cav3.2 和 Cav3.3 的 IC50 分别为 310 nM 和 270 nM。

原价
¥1987-8325
价格
1590-6660
ML 218 hydrochloride的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajci15014
  • CAS: 1346233-68-8
  • 别名:
  • 分子式: C19H26Cl2N2O.HCl
  • 分子量: 405.79
  • 纯度: >98%
  • 溶解度: Soluble in DMSO
  • 储存: Store at -20°C
  • 库存: 现货

Background

ML218 is a selective T-type calcium channel inhibitor with IC50s of 270 and 310 nM for Cav3.3 and Cav3.2 in electrophysiology assay, respectively.


ML218 (CID 45115620) inhibits Cav3.1, Cav3.2, Cav3.3[1].


Electrophysiology studies in STN neurons demonstrate robust effects of ML218 on the inhibition of T-type calcium current, inhibition of low threshold spike, and rebound burst activity. ML218 was found to be orally efficacious in a dose-dependent manner in a preclinical Parkinson’s disease model, haloperidol-induced catalepsy, and comparable to clinically validated A2A antagonism[1]. ML218 reaches a peak cerebrospinal fluid concentration 1-2 hrs after s.c. administration. No effects of ML218 on cardiac rhythmicity is found in electrocardiographic studies. ML218 does not have antiparkinsonian effects in MPTP-treated parkinsonian monkeys, due at least in part, to the agent’s sedative effects[2].


参考文献:
[1]. Xiang Z, et al. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
[2]. https://www.ncbi.nlm.nih.gov/pubmed/22368764

Protocol

Animal experiment:

Rats: ML218 is administered intravenously (IV) to rats via the jugular vein catheter in 20% DMSO/80% saline at a dose of 1 mg/kg and a dose volume of 1 mL/kg. Blood collections via the carotid artery are performed at predose, and at 2 min, 7 min, 15 min, 30 min, and 1 h, 2 h, 4 h, 7 h, and 24 h post dose. Samples are collected into chilled, EDTA-fortified tubes, and centrifuged for 10 min at 3000 rpm (4°C), and resulting plasma is aliquoted into 96-well plates for LC/MS/MS analysis. For oral exposure studies, measuring both systemic plasma and CNS tissue exposure, ML218 is administered (oral gavage) to fasted rats as suspensions in 10% Tween 80/0.5% methylcellulose at a dose of 10 mg/kg and in a dosing volume of 10 mL/kg; blood and whole brain samples are collected at 1.5 h post dose. Blood is collected into chilled, EDTA-fortified tubes, centrifuged for 10 min at 3000 rpm (4°C), and stored at ?80 °C until LC/MS/MS analysis[1].

参考文献:

[1]. Xiang Z, et al. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
[2]. https://www.ncbi.nlm.nih.gov/pubmed/22368764

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服